AACR logo

More articles from Therapeutic Agents: Biological

Abstract LB-C08: Imipridone ONC212 induces apoptosis, suppresses autophagy and synergizes upon GRP132 knockdown or exposure to lactic acid in preclinical studies of the pancreatic cancer microenvironment
Isacco Ferrarini, Aakash Jhaveri, Young Lee, Howard Safran, Lanlan Zhou, Wafik S El-Deiry

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) LB-C08; DOI: 10.1158/1535-7163.TARG-19-LB-C08
Abstract CN07-02: Immunotoxins targeting GPC3 for liver cancer
Mitchell Ho, Bryan D Fleming, Tim F Greten, Ira Pastan

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) CN07-02; DOI: 10.1158/1535-7163.TARG-19-CN07-02
Abstract LB-C07: Preclinical evaluation of MCLA-129: A bispecific antibody targeting c-MET and EGFR
Cecile Geuijen, Mario di Matteo, Tristan Gallenne, Sarah Trusso Cafarello, Roy Nijhuis, Therese Visser, Willem Bartelink, Carina Bartelink-Clements, Berina Eppink, Rinse Klooster, John dekruif, Massimiliano Mazzone, Mark Throsby

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) LB-C07; DOI: 10.1158/1535-7163.TARG-19-LB-C07
Abstract CN01-02: Maximizing the potential of bispecific antibodies for cancer drug development
Paul W H I Parren

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) CN01-02; DOI: 10.1158/1535-7163.TARG-19-CN01-02
Abstract C031: Ras processing by RRSP protease as a strategy to inhibit Ras-driven tumors
Vania Vidimar, Greg L Beilhartz, Roman A Melnyk, Karla JF Satchell

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C031; DOI: 10.1158/1535-7163.TARG-19-C031
Abstract C026: DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models
Daisuke Okajima, Junko Yamaguchi, Michiko Kitamura, Reiko Kamei, Takanori Maejima, Tomoko Shibutani, Satoru Yasuda, Tadashi Toki, Tsuyoshi Karibe, Tomomichi Fujitani, Takashi Nakada, Riki Goto, Yutaka Noguchi, Yuki Abe, Toshinori Agatsuma

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C026; DOI: 10.1158/1535-7163.TARG-19-C026
Abstract C032: A novel integrin-targeted therapeutic agent for ovarian cancer
Franics S Markland, Steve Swenson, Radu Minea, Louis Dubeau

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C032; DOI: 10.1158/1535-7163.TARG-19-C032
Abstract C027: A Phase I, dose finding study of BI 754111, an anti-LAG-3 antibody, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumors: preliminary results from the microsatellite stable (MSS) metastatic colorectal cancer (mCRC) cohort
Johanna Bendell, Susanna V Ulahannan, Quincy Chu, Manish Patel, Ben George, Renee Landsberg, Mabrouk Elgadi, Christine Duffy, Ralph Graeser, Wenbo Tang, Michael Merger, Miaomiao Ge, Melissa Johnson

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C027; DOI: 10.1158/1535-7163.TARG-19-C027
Abstract C034: Cancer-specific intracellular delivery of therapeutic antibodies against RAS
Michael J McGuire, Susan Li, Curtis A Allred, Indu Venugopal, Claire Gormley, Kathlynn C Brown

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C034; DOI: 10.1158/1535-7163.TARG-19-C034
Abstract C033: HPN328: An anti-DLL3 T cell engager for treatment of small cell lung cancer
Wade H Aaron, Richard Austin, Manasi Barath, Evan Callihan, Michael Cremin, Thomas Evans, Maria Gamez, Vaishnavi Ganti, Golzar Hemmati, Kathryn Kwant, Che-Leung Law, Bryan Lemon, Llewelyn Lao, Mary Ellen Molloy, Jessica O’Rear, Laura Sun, Holger Wesche, Stephen Yu, Timothy Yu

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C033; DOI: 10.1158/1535-7163.TARG-19-C033

Main menu

User menu

Search

More articles from Therapeutic Agents: Biological

Pages

Articles

Info for

About MCT